ferriprive anemia iron deficiency anemia
Conditions
Interventions
None listed
Sponsors
Universitair Medisch Centrum Sint Radboud
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: -above 18 years old -an active chronic inflammatory or infectious disorder with CRP >10 mg/L (defined by the treating medical specialist) - anemia (defined as hemoglobin concentration below 7.0 mmol/l and 7.5 mmol/l for women and male, respectively).
Exclusion criteria
Exclusion criteria: -not able to take oral medication -using iron supplements in the previous month -using erythropoietin -requiring blood transfusion -renal and liverfailure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main study parameter is to determine whether the change in Ret- He, RBC- He and hepcidin concentration from baseline to one or two weeks iron supplemental therapy predicts the increase in hemoglobin concentration after 6 weeks of oral iron supplementation therapy; | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary objectives are to (1) assess the predicting value of Ret- He, RBC- He and hepcidin concentration at baseline (before therapy) to increase the hemoglobin concentration after six weeks of oral iron supplementation therapy; (2) to compare the value of conventional iron status parameters ferritin, transferrin saturation, soluble transferrin receptor and iron with the novel iron parameters to predict the response of one, two and six weeks oral iron supplementation therapy defined by an increase in hemoglobin concentration. | — |
Countries
Netherlands
Outcome results
None listed